PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING MIR-324 and TUT4/7 EXPRESSION MODULATORS

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising miR-324 and TUT4/7 expression modulators, wherein the pharmaceutical composition of the present invention can prevent cell division and hinder cancer development by inhibiting the function of TUT4/7, and can increase the amount of miR-324-5p and suppress the function of miR-324-3p.1, and therefore can be effectively used for prevention, treatment, or diagnosis of cancer.

What is claimed is: 
     
         1 . Method of treating cancer, comprising administering to a subject in need thereof a pharmaceutical composition for preventing or treating cancer, the composition comprising a microRNA(miRNA) which is comprising i) a miR-324-5p or an isoform thereof, and ii) a miR-324-3p or an isoform thereof:
 wherein the i) miR-324-5p comprising the nucleotide sequences of SEQ ID NO: 47 at the 5′ end, and a total of 20 to 24 nucleotide sequences;   wherein the ii) miR-324-3p is,
 a) the first base from the 5′ end may be C or G; 
 b) the first base from the 5′ end is complementary to the 20th base from the 5′ end of the miR-324-5p; and 
 c) the 20th base from the 5′ end may be A, U, or C. 
   
     
     
         2 . The method of  claim 1 , wherein the microRNA is in the form of a duplex in which i) miR-324-5p or isoform thereof, and the ii) miR-324-3p or isoform thereof are bounded to each other. 
     
     
         3 . The method of  claim 1 , wherein the 5′ end of the i) miR-324-5p or isoform thereof, and the ii) miR-324-3p or isoform thereof bonded to phosphate, respectively. 
     
     
         4 . The method of  claim 1 , wherein the i) miR-324-5p or isoform thereof, comprising the nucleotide sequences of SEQ ID NO: 1 or 32. 
     
     
         5 . The method of  claim 1 , wherein the ii) miR-324-3p or isoform thereof, comprising the nucleotide sequences of SEQ ID NO: 2, 3, or 33. 
     
     
         6 . The method of  claim 1 , wherein the cancer is selected from the group consisting of colon cancer, large intestine cancer, lung cancer, liver cancer, stomach cancer, gallbladder cancer, kidney cancer, uterine cervical cancer, endometrial cancer, ovarian cancer, breast cancer, brain cancer, head and neck cancer, and malignant melanoma. 
     
     
         7 . A method of treating cancer, comprising:
 administering to a subject in need thereof a pharmaceutical composition for preventing or treating cancer, the composition comprising at least one selected from the group consisting of:   a nucleic acid composed of the nucleotide sequence of SEQ ID NO: 4; and   a small interfering RNA (siRNA) comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 5 to 20.   
     
     
         8 . The method of  claim 7 , wherein the small interfering RNA is in a duplex form in which:
 i) a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 5 to 8 and a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 9 to 12 bind to each other; or   ii) a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 13 to 16 and a small interfering RNA comprising any one of the nucleotide sequences of SEQ ID NOS: 17 to 20 bind to each other.   
     
     
         9 . The method of  claim 7 , wherein the cancer is selected from the group consisting of encephaloma, colon cancer, large intestine cancer, lung cancer, liver cancer, stomach cancer, esophageal cancer, pancreatic cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, testis cancer, uterine cervical cancer, endometrial cancer, choriocarcinoma, ovarian cancer, breast cancer, thyroid cancer, brain cancer, head and neck cancer, and malignant melanoma. 
     
     
         10 . A method of diagnosing cancer, comprising measuring a level of:
 i) at least one miRNA selected from the group consisting of miR-324-5p and miR-324-3p.1; or   ii) at least one gene mRNA or protein thereof selected from the group consisting of TUT4 (terminal uridylyl transferases 4) and TUT7 (terminal uridylyl transferases 7).   
     
     
         11 . The method of  claim 10 ,
 wherein the measuring step is performed by an agent that measures the level of miRNA;   wherein the agent comprises a primer or a probe which bind specifically to the at least one miRNA.   
     
     
         12 . The method of  claim 10 ,
 wherein the measuring step is performed by an agent that measures the level of gene mRNA;   wherein the agent for measuring an mRNA level comprises a primer or a probe which bind specifically to at least one mRNA of TUT4 and TUT7.   
     
     
         13 . The method of  claim 10 ,
 wherein the measuring step is performed by an agent that measures the level of protein;   wherein the agent for measuring a protein level comprises an antibody binding specifically to at least one protein of TUT4 and TUT7.